Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin

Oncology Reports

Volumn 10, Issue 1, 2003, Pages 163-167

  Catino, Annamaria ^a   Crucitta, Enrico ^a   Latorre, Agnese ^a   Sambiasi, Domenico ^a   Calabrese, Pietro ^a   Lorusso, Vito ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Amifostine; Breast cancer; Doxorubicin

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; DOXORUBICIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; HEMATOLOGIC DISEASE; HUMAN; METASTASIS; MIDDLE AGED; PATHOLOGY; SOFT TISSUE TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BONE NEOPLASMS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; SOFT TISSUE NEOPLASMS; SURVIVAL RATE;

EID: 0242382913     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.1.163     Document Type: Article

References (28)

1. Capizzi RL: Protection of normal tissues from the cytotoxic effect of chemotherapy by Amifostine (Ethyol): clinical experience. Semin Oncol 21 (Suppl 1): 8-15, 1994.
2. Capizzi RL: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by Amifostine. Semin Oncol 26 (Suppl 7): 3-21, 1999.
3. Van der Vjigh WJF and Peters GJ: Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by Amifostine (Ethyol): preclinical aspects. Semin Oncol 21: 2-7, 1994.
4. Yuhas JM and Starer JB: Differential chemo-protection of normal and malignant tissues. J Natl Cancer Inst 42: 331-335, 1979.
5. Yuhas JM: Active versus passive absorption kinetics for selective protection of normal tissues by 5-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 40: 1519-1524, 1980.
6. Grdina DJ and Sigdestad CP: Radiation protectors: the unexpected benefits. Drug Metab Rev 20: 13-42, 1989. (Pubitemid 19112898)
7. Nagy B, Dale PJ and Grdina DJ: Protection against cis-Diammine-dichloro- platinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)amino] ethanethiol. Cancer Res 46: 1132-1135, 1986. (Pubitemid 16048243)
8. Nagy B and Grdina DJ: Protective effects of 2-[(aminopropy-l) amino]ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cells. Int J Radiat Oncol Biol Phys 12: 1475-1478, 1986. (Pubitemid 16030642)
9. Grdina DJ, Nagy B and Sigdestad CP: Radioprotectors in treatment therapy to reduce risk in secondary tumor induction. Pharmacol Ther 39: 21-25, 1988.
10. Milas L, Hunter NR, Stephens LC, et al: Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethyl-phosphorothioic acid. Cancer Res 44: 5567-5569, 1984. (Pubitemid 15183558)
11. Glover DJ, Glick JH, Weiler C, et al: Phase I/II trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 12: 1509-1512, 1986. (Pubitemid 16030650)
12. Glover DJ, Glick JH, Weiler C, et al: WR-2721 and high-dose cisplatin: an active combination in tile treatment of metastatic melanoma. J Clin Oncol 5: 574-578, 1987. (Pubitemid 17062494)
13. Glover DJ, Glick JH, Weiler C, et al: WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 4: 584-588, 1986. (Pubitemid 16117952)
14. Mollman JE, Glover DJ, Hogan WM, et al: Cisplatin neuropathy: risk factors, prognosis and protection by WR-2721. Cancer 61: 2192-2195, 1988.
15. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-related toxicities: results of a randomized controlled trial in patents with advanced ovarian cancer. J Clin Oncol 14: 2101-2112, 1996. (Pubitemid 26230113)
16. Liu T, Liu Y, He S, et al: The use of radiation with or without amifostine in advanced rectal cancer. Cancer 69: 2820-2825, 1992.
17. Schiller JH, Storer B, Berlin J, et al: Amifostine, cisplatin and vinblastine in metastatic non-small cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 14: 1913-1921, 1996. (Pubitemid 26185466)
18. Tannehill SP, Mehta MP, Larson M, et al: Effect of Amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small cell lung cancer: results of a phase II trial. J Clin Oncol 15: 2850-2857, 1997. (Pubitemid 27330012)
19. Dobric S, Dragojevic-Simic V, Bokonjic D, Milovanovic S, Marincic D and Jovic P: The efficacy of selenium, WR-2721, and their combination in the prevention of adriamycin-induced cardiotoxicity in rats. J Environ Pathol Toxicol Oncol 17: 291-299, 1998. (Pubitemid 28380876)
20. Dorr RT: Cytoprotective agents for anthracyclines. Semin Oncol 23 (Suppl 8): 23-34, 1996.
21. Dorr RT, Lagel K and McLean S: Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro. Eur J Cancer 32A (Suppl 4): S21-S25, 1996.
22. Nazeyrollas P, Prevost A, Baccard N, Manot L, Devillier P and Millart H: Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol 43: 227-232, 1999. (Pubitemid 29042491)
23. WHO: Handbook for Evaluating Response and Toxicity from Chemotherapy. Geneva, 1989.
24. Taylor SG and Gelber RD: Experience of the Eastern Cooperative Oncology Group with doxorubicin as single agent in patients with previously untreated breast cancer. Cancer Treat Rep 66: 1594-1595, 1982.
25. A'Hern RP, Smith IE, Ebbs SR, et al: Chemotherapy and survival in advanced breast cancer: the inclusion of Doxorubicin in Cooper Type regimens. Br J Cancer 67: 801-805, 1993. (Pubitemid 23101563)
26. Tranum DL, McDonald D, Thigpen T, et al: Adriamycin combinations in advanced breast cancer. Cancer 49: 835-839, 1982.
27. Irwin LE, Chlebowski RT, Weiner JM, et al: Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group Trial. Cancer Treat Rep 64: 981-984, 1980. (Pubitemid 11139841)
28. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354, 1999. (Pubitemid 29368232)